首页> 外文期刊>Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research >Hospital contacts due to hepatobiliary adverse events in > 5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries

【24h】

Hospital contacts due to hepatobiliary adverse events in > 5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries

机译：由于肝胆道不良事件的医院接触> 5000名患有发起者或生物仿生患者的炎症关节疾病（SB4）：丹比奥和国家注册管理机构之间的观察全国范围内的研究

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research》 |2020年第6期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类免疫性疾病;
关键词

相似文献

外文文献

1. Hospital contacts due to hepatobiliary adverse events in > 5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries [J] . Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2020,第6期

机译：由于肝胆道不良事件的医院接触> 5000名患有发起者或生物仿生患者的炎症关节疾病（SB4）：丹比奥和国家注册管理机构之间的观察全国范围内的研究
2. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry [J] . Glintborg Bente, Loft Anne Gitte, Omerovic Emina, Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2019,第2期

机译：切换或不切换：从发起者到生物仿制物的强制性切换的全国性指南的结果。 2061例丹比奥登记处炎症关节炎患者的一年治疗结果
3. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2061 patients with inflammatory arthritis followed in the DANBIO registry [J] . Glintborg B., Sorensen I. J., Omerovic E., Scandinavian journal of rheumatology . 2018,第Suppla129期

机译：一年治疗保留在全国性非医疗开关后从发起者到生物仿生素肠道患者，炎症关节炎患者患者丹比奥登记处
4. Switching patients with inflammatory arthritis from Etanercept (Enbrel®) to the biosimilar drug SB4 (Benepali®): A single-centre retrospective observational study in the UK and a review of the literature [O] . Anastasia-Vasiliki Madenidou, Andrew Jeffries, Sneha Varughese, 2019

机译：将炎症性关节炎患者从Etanercept（Enbrel®）转向生物仿制药SB4（Benepali®）：在英国的单中心回顾性观察研究并进行了文献综述
5. FRI0103 One-year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. an observational danbio study [O] . B. Glintborg, I.J. Sørensen, E. Omerovic, 2018

机译：Fri0103一年的全国性炎性关节炎患者的一年后续随从发起者转向生物仿制物的entaneAncept，专注于转回发起者的患者。一个观察丹比奥研究

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号